Home・Stock List・Gossamer Bio Inc

Gossamer Bio Inc

Open

SectorHealthcare

0.17

Buy Sell

Overview

Share price change

24h

Current

Min

0.16

Max

0.18

Key metrics
By Trading Economics
Income	574K -47M
Sales	3.2M 17M
EPS	-0.2
Profit margin	-275.223
Employees	161
EBITDA	2.1M -44M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+529.41% upside

Dividends
By Acuity
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	18M 97M
Previous open	0.17
Previous close	0.17

News Sentiment

By Acuity

63%

37%

285 / 340 Healthcare

Gossamer Bio Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1 Aug 2026, 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31 Jul 2026, 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30 Jul 2026, 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29 Jul 2026, 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28 Jul 2026, 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27 Jul 2026, 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24 Jul 2026, 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23 Jul 2026, 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22 Jul 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21 Jul 2026, 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20 Jul 2026, 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Peer Comparison

Price change

Gossamer Bio Inc Forecast

Price Target

By TipRanks

529.41% upside

12 Months Forecast

Average 1.07 USD 529.41%

High 2 USD

Low 0.28 USD

Based on 5 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.

Sentiment

By Acuity

285 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.